1. Medtech Insight
  2. >>Leadership

Caszyme CEO Says CRISPR Gene Editing Could Help Patients, Save The Planet

 
• By Ayisha Sharma

Caszyme CEO and 2022 In Vivo Rising Leader Monika Paule is on a mission to expand the CRISPR toolbox of available proteins to enhance diagnostic tools, therapeutics and even agricultural practices.

Gene Editing_651647128_1200.jpg

2021 was a strong year for CRISPR gene editing, with the first in vivo data released by Intellia Therapeutics, Inc. and Regeneron Pharmaceuticals, Inc. appearing to validate the novel approach. While CRISPR technology is perhaps best known for therapeutic applications in rare diseases, Monika Paule, CEO of Caszyme, believes this is just the tip of the iceberg.

Paule starts our call by apologizing for her dog barking in the background. Her pet is not usually this loud,...

Welcome to Medtech Insight

Create an account to read this article

Already a subscriber?

More from Leadership

Bivacor Rotary Heart Could Upend The Artificial Heart Market, If It Reaches Its Destination

 
• By Marion Webb

Bivacor aims to be first to the US market with a permanent total artificial heart, starting with use as a bridge to transplant. CMO William Cohn says data from countries with low transplant rates could support pivotal trials and long-term use.

Execs On The Move: June 30–July 4, 2025

 
• By Medtech Insight Team

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.

HealthAI: ‘Established Regulations Already Exist For Regulating AI In Healthcare Safely’

 
• By Natasha Barrow

Paul Campbell, chief regulatory officer at HealthAI, emphasizes existing regulations for AI in healthcare should not be overlooked as new regulations are developed.

From Imitation To Action: Johns Hopkins Robot Autonomously Performs Key Step In Gallbladder Surgery

 
• By Marion Webb

Researchers at Johns Hopkins have used a robotic system to autonomously perform a key part of gallbladder surgery without a surgeon's hand. Lead author Axel Krieger says it could take five to 10 years before an autonomous robotic system will reach human trials and expects regulatory hurdles.

More from Medtech Insight

Ochsner Surgeon In ‘The Big Easy’ Eases Patient’s Pain With Skill And Virtual Reality

 
• By Brian Bossetta

A surgeon at Ochsner Health in New Orleans was able to successfully remove a rare and dangerous tumor from a patient’s spine using cutting-edge technology that would have otherwise made the procedure too risky.

Execs On The Move: June 30–July 4, 2025

 
• By Medtech Insight Team

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.

FDA Commissioner’s Voucher Program Should Include Devices, Transplant Technology Firm Says

 
• By Elizabeth Orr

The FDA's new Commissioner’s National Priority Voucher program aims to expedite drug approvals significantly. Device firms like XVIVO advocate for a similar initiative for devices, emphasizing the potential for faster reviews and improved patient access to lifesaving technologies.